Sign in to view content

Novel Vascular Endothelial Growth-Factor A (VEGF-A) and Angiopoietin-2 (Ang-2) Bispecific Protein, RO-634, in Comparison to Aflibercept

Mark R. Barakat, MD

Video
Published 2022

Related

Two years visual acuity and anatomical outcomes of patients with diabetic macular oedema treated with intravitreal aflibercept in a real life setting
Marko Lukic, MD PhD FEBO FASRS
On Demand Cases, Courses, and Papers
2019
Clinical Features and Outcomes of Infants With Retinopathy of Prematurity Who Fail Anti-VEGF Therapy (FELLOWS FORUM AWARD WINNER)
Lucy T Xu, MD
Annual Meeting Talks
2021
Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibiz
Susan B. Bressler, MD, FASRS
Updates from the Field
2017

Category: Pharmacology

See more